Efectos de nuevos agentes regenerativos biomiméticos sobre la cicatrización corneal en un modelo experimental de úlceras posquirúrgicas

Alcalde, Ignacio; Íñigo-Portugués, Almudena; Carreño, Néstor I.; Riestra, Ana Cristina; Merayo‐Lloves, Jesús

doi:10.1016/j.oftal.2015.04.006

Cited by 20 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the effectiveness of RGTA has been demonstrated in the closure of NCU 2,20 , and for the treatment of accidental injuries (cornea burns) 21 . The RGTA matrix has also shown to be useful in the closure of corneal ulcers in an animal model of photorefractive keratectomy (PRK) surgery 22 .…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To provide the efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers.Methods: This retrospective study included patients from Fernandez-Vega University Institute between 2010 and 2019, with noninfectious corneal ulcers and no response to standard treatments. RGTA treatment was firstly applied (1 drop every two days), but if ulcer closure was not achieved, PRGF eye drops treatment was added (4 times/day). The time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. The presence of adverse events along the follow-up period was also reported. Results: Seventy-four patients (79 eyes) were included in the study, forty-six eyes (62.2%) were women, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder found in the patients of the study (n = 27, 34.2%), mainly due to the herpes virus (n = 15, 19.0%). The mean time of PRGF eye drops treatment associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved significantly from the baseline (p<0.001), while IOP remained unchanged (p=0.665). No adverse events were recorded. Conclusions: The use of RGTA and PRGF in noninfectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In this model, RGTA ® reduced the expression of enzymes generating superoxide radicals and nitric oxide as well as proteolytic enzymes, thereby fulfilling a dual role: protecting the cornea from damage induced by excessive proteolysis as well as toxic oxygen and nitrogen products [30]. Furthermore, in a mouse model of corneal ulcers following photorefractive keratectomy (PRK), RGTA ® treatment increased the degree of corneal transparency and improved corneal epithelial cytoarchitecture and nerve regeneration, and decreased or delayed the presence of stromal myofibroblasts [52]. …”

Section: Rgta® Pre-clinical Modelsmentioning

confidence: 99%

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

et al. 2016

View full text Add to dashboard Cite

The importance of extracellular matrix (ECM) integrity in maintaining normal tissue function is highlighted by numerous pathologies and situations of acute and chronic injury associated with dysregulation or destruction of ECM components. Heparan sulfate (HS) is a key component of the ECM, where it fulfils important functions associated with tissue homeostasis. Its degradation following tissue injury disrupts this delicate equilibrium and may impair the wound healing process. ReGeneraTing Agents (RGTA®s) are polysaccharides specifically designed to replace degraded HS in injured tissues. The unique properties of RGTA® (resistance to degradation, binding and protection of ECM structural and signaling proteins, like HS) permit the reconstruction of the ECM, restoring both structural and biochemical functions to this essential substrate, and facilitating the processes of tissue repair and regeneration. Here, we review 25 years of research surrounding this HS mimic, supporting the mode of action, pre-clinical studies and therapeutic efficacy of RGTA® in the clinic, and discuss the potential of RGTA® in new branches of regenerative medicine.

show abstract

“…Cacicol, which is a structural analogue of glycosaminoglycans, mimics heparin sulfate (HS) and is thought to replace the degraded HS and produce a suitable environment for recruiting growth factors necessary for corneal repair, especially in eyes with PED. 13 …”

Section: Discussionmentioning

confidence: 99%

Unusual Course of Crystalline Keratopathy in a Patient with Graft-Versus-Host Disease

Bostanci

2017

tjo

View full text Add to dashboard Cite

We present a case of infectious crystalline keratopathy in a patient with Graft-versus-Host disease (GVHD) who developed satellite fungal keratitis. A 51-year-old man was referred for bilateral total persistent corneal epithelial defects with severe dry eye. Although persistent epithelial defect healed with medical therapy, he developed stromal keratitis with satellite lesions confirmed to be secondary to Candida albicans. After three months of antifungal treatment and debridement, improvement of the infiltrates was obtained. Crystalline keratopathy is an important clinical entity which may develop due to several causes. The microbial causes include not only bacteria but fungi as well. Careful investigation must be performed, especially for immune-compromised patients, in order to provide appropriate and timely treatment.

show abstract

Efectos de nuevos agentes regenerativos biomiméticos sobre la cicatrización corneal en un modelo experimental de úlceras posquirúrgicas

Cited by 20 publications

References 48 publications

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

Unusual Course of Crystalline Keratopathy in a Patient with Graft-Versus-Host Disease

Contact Info

Product

Resources

About